StockData
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. (TVRD) stock

TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.01−0.09 (-8.18%)

Close on Nov 17, 2026Market cap $13.47MP/E –Yield 0.00%

Tvardi Therapeutics cash

Cash and short-term investments held at the end of each period.

Tvardi Therapeutics's cash was $15.77M at Jun 30, 2026. For fiscal 2025 it was $30.81M, down 18.7% from the year before. Over ten years it grew -11.7% a year on average. The highest annual figure on record is $251.49M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$30.81M-18.7%
FY2024Dec 31, 2024$37.90M-62.4%
FY2023Dec 31, 2023$100.76M-35.7%
FY2022Dec 31, 2022$156.75M-33.8%
FY2021Dec 31, 2021$236.79M-5.8%
FY2020Dec 31, 2020$251.49M+15.3%
FY2019Dec 31, 2019$218.17M+19.4%
FY2018Dec 31, 2018$182.78M+97.5%
FY2017Dec 31, 2017$92.57M+58.8%
FY2016Dec 31, 2016$58.28M-45.4%
FY2015Dec 31, 2015$106.74M+102.7%
FY2014Dec 31, 2014$52.66M+326.2%
FY2013Dec 31, 2013$12.36M+1006.3%
FY2012Dec 31, 2012$1.12M-72.7%
FY2011Dec 31, 2011$4.10M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$15.77M-61.5%
Q1 FY2026Mar 31, 2026$24.98M+118.4%
Q4 FY2025Dec 31, 2025$30.81M-18.7%
Q3 FY2025Sep 30, 2025$36.46M-13.3%
Q2 FY2025Jun 30, 2025$40.99M-27.6%
Q1 FY2025Mar 31, 2025$11.44M-83.6%
Q4 FY2024Dec 31, 2024$37.90M-62.4%
Q3 FY2024Sep 30, 2024$42.04M-49.5%
Q2 FY2024Jun 30, 2024$56.62M-44.4%
Q1 FY2024Mar 31, 2024$69.77M-43.4%
Q4 FY2023Dec 31, 2023$100.76M-35.7%
Q3 FY2023Sep 30, 2023$83.29M-53.6%
Q2 FY2023Jun 30, 2023$101.74M-50.3%
Q1 FY2023Mar 31, 2023$123.36M-41.1%
Q4 FY2022Dec 31, 2022$156.75M-33.8%
Q3 FY2022Sep 30, 2022$179.53M-7.2%
Q2 FY2022Jun 30, 2022$204.68M-1.3%
Q1 FY2022Mar 31, 2022$209.57M-8.2%
Q4 FY2021Dec 31, 2021$236.79M-5.8%
Q3 FY2021Sep 30, 2021$193.42M+47.2%
Q2 FY2021Jun 30, 2021$207.39M+35.5%
Q1 FY2021Mar 31, 2021$228.31M+27.0%
Q4 FY2020Dec 31, 2020$251.49M+15.3%
Q3 FY2020Sep 30, 2020$131.38M-47.3%
Q2 FY2020Jun 30, 2020$153.05M+12.8%
Q1 FY2020Mar 31, 2020$179.76M+15.1%
Q4 FY2019Dec 31, 2019$218.17M+19.4%
Q3 FY2019Sep 30, 2019$249.07M+20.9%
Q2 FY2019Jun 30, 2019$135.63M+2.8%
Q1 FY2019Mar 31, 2019$156.14M+109.5%
Q4 FY2018Dec 31, 2018$182.78M+97.5%
Q3 FY2018Sep 30, 2018$206.08M+100.1%
Q2 FY2018Jun 30, 2018$131.96M+17.4%
Q1 FY2018Mar 31, 2018$74.52M+102.4%
Q4 FY2017Dec 31, 2017$92.57M+58.8%
Q3 FY2017Sep 30, 2017$102.98M+44.2%
Q2 FY2017Jun 30, 2017$112.44M–
Q1 FY2017Mar 31, 2017$36.81M–
Q4 FY2016Dec 31, 2016$58.28M–
Q3 FY2016Sep 30, 2016$71.42M–

More Tvardi Therapeutics figures

See a number that looks wrong?